Interim Effectiveness of the Influenza Vaccine for the 2024-2025 Respiratory Viral Season

Nabin K. Shrestha,[1] Patrick C. Burke,[2] Amy S. Nowacki,[3] Steven M. Gordon[1]

[1]Departments of Infectious Diseases, [2]Infection Prevention, [3]Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.

Keywords: influenza; vaccine effectiveness; vaccines;

Running Title: Influenza vaccine effectiveness

Correspondence: N. K. Shrestha, 9500 Euclid Avenue / G-21, Cleveland, OH 44195, USA
(shrestn@ccf.org)

Alternate corresponding author: S. M. Gordon, MD, 9500 Euclid Avenue / G-21, Cleveland, OH 44195, USA (gordons@ccf.org)

Summary: Among 53321 working-aged Cleveland Clinic employees, we were unable to find that the influenza vaccine has been effective in preventing infection during the 2024-2025 respiratory viral season thus far.

ABSTRACT

Background. The purpose of this study was to evaluate the effectiveness of the influenza vaccine during the 2024-2025 viral respiratory season.

Methods. Employees of Cleveland Clinic in employment in Ohio on October 1, 2024, were included. The cumulative incidence of influenza among those in the vaccinated and unvaccinated states was compared over the following weeks. Protection provided by vaccination (analyzed as a time-dependent covariate) was evaluated using Cox proportional hazards regression. The analysis was adjusted for age, sex, job type, employment location, and eagerness to get vaccinated.

Results. Among 53321 employees, 43771 (82.1%) had received the influenza vaccine by the end of the study. Influenza occurred in 324 (0.6%) during the study. In an analysis adjusted for age, sex, job type, employment location, and eagerness to get vaccinated, the risk of influenza was not significantly different between the vaccinated and unvaccinated states (HR, 1.10; 95% C.I., .77 - 1.57; $P = 0.59$), yielding a calculated vaccine effectiveness of -10.1% (95% C.I. -57.0 - 22.7%).

Conclusions. This study has been unable to find that the influenza vaccine given to working-aged adults has provided protection overall against influenza during the 2024-2025 respiratory viral season thus far.

INTRODUCTION

Influenza is a common respiratory viral infection with potential for substantial mortality and morbidity, and was estimated to be responsible for 145 000 deaths worldwide among all ages in 2017 [1]. The mortality could be much higher when there are pandemics of illness, which occur periodically, the most devastating recorded one being the influenza pandemic of 1918 which was estimated to have a case fatality rate of 2.5% and was considered to be responsible for more than 50 million deaths worldwide [2]. There is a seasonal pattern to illness, with most infections occurring during the winter months [3]. The influenza virus evolves over time [4], and as this happens an increasingly larger proportion of the population becomes susceptible to the newly evolved strains.

Influenza is also a vaccine-preventable illness. However, influenza vaccines do not induce long-lasting antibody titers, and annual influenza vaccination is recommended at the beginning of each respiratory viral season in the autumn months in the northern hemisphere. Additionally, the effectiveness of the vaccine in any given year depends on how similar the strains contained in the vaccine are to the strains causing infection that year. The most widely used seasonal influenza vaccine is the trivalent inactivated vaccine (TIV), which is composed of two influenza A virus types (H3N2 and H1N1) and an influenza B virus type [5]. A new vaccine is produced each year in an attempt to match the vaccine strains to the strains projected to be most prominent in the upcoming influenza season. Since the current process of developing the vaccine typically takes a few months, a decision on which strains to include in the vaccine must be made several months in advance. In years where there is a good match between the vaccine strains and the infecting strain, vaccine effectiveness is expected to be good. In years where there is a poor match between vaccine strains and the circulating infecting strain, vaccine effectiveness is expected to be poor.

Given the high morbidity and mortality burden of influenza, universal annual vaccination against the infection is recommended by the Advisory Committee on Immunization Practices [6]. Over the last

couple of decades, policies of mandatory annual vaccination of healthcare personnel have been increasingly adopted across healthcare institutions [7].

Healthcare resource utilization, including hospitalizations, and resource needs such as quantity of antiviral medications needed, are strongly affected by how effective the vaccine is during any respiratory viral season. Early estimates of vaccine effectiveness of the influenza vaccine during any respiratory viral season can provide information that can help healthcare institutions and pharmacies prepare for the remainder of the season.

The purpose of this study was to evaluate the effectiveness of the influenza vaccine during the early part of the 2024-2025 respiratory viral season in North America.

METHODS

Study design

This was a prospective cohort study conducted at the Cleveland Clinic Health System (CCHS) in the United States. The study was approved by the Cleveland Clinic Institutional Review Board as exempt research (IRB no. 23-625). A waiver of informed consent and waiver of HIPAA authorization were approved to allow the research team access to the required data.

Setting

For several years Cleveland Clinic has had a mandatory participation influenza vaccination program, which requires employees to either receive an annual influenza vaccine or seek an exemption on medical or religious grounds. The vaccine is provided to healthcare personnel free of charge. When healthcare personnel develop acute respiratory illnesses, they are encouraged to seek medical attention and the decision to test for influenza is made on a case-by-case basis by the treating provider either in the Occupational Health clinics or at their personal provider's office.

Participants

CCHS employees in employment at any Cleveland Clinic location in Ohio on the study start date were included in the study. Those for whom age or sex data were missing were excluded.

Variables

Variables collected were influenza vaccination date, age, sex, job location, job type categorization into clinical or non-clinical, and date of positive test for influenza. Institutional data governance around employee data limited our ability to collect additional clinical variables.

A variable called "eagerness to get vaccinated" was defined as being "high" for individuals vaccinated within less than 21 days of the vaccine becoming available and "low" for the remaining individuals.

Influenza was defined as a positive nucleic acid amplification test or rapid antigen detection test for influenza A or B any time after the study start date. Only molecular and point-of-care tests performed within Cleveland Clinic Health System were included.

Outcome

The study outcome was time to influenza. Outcomes were followed until January 29, 2025.

Statistical analysis

For the 2024-2025 influenza season, the vaccine became available on 1 October 2024. This date was considered the study start date.

A Simon-Makuch hazard plot [8] was created to compare the cumulative incidence of influenza in the vaccinated and non-vaccinated states, by treating influenza vaccination as a time-dependent covariate [9,10]. Individuals were considered vaccinated 7 days after receipt of a single dose of an influenza vaccine. Subjects who had not developed influenza were censored at the end of the study follow-up period. Those whose employment was terminated during the study period before they had influenza were censored on the date of termination of employment. Curves for the non-vaccinated state were based on data while the vaccination status of subjects remained "non-vaccinated". Curves for the vaccinated state were based on data from the date the influenza vaccination status changed to "vaccinated".

Multivariable Cox proportional hazards regression models were fit to examine the association of various variables with time to influenza. Influenza vaccination was included as a time-dependent covariate. Variance inflation factors were evaluated to ensure that there was no multicollinearity in the models. The proportional hazards assumption was checked by examining Schonfeld residuals and there were no

significant violations. Vaccine effectiveness (VE) was calculated from the hazard ratios (HR) for influenza vaccination in the models using the formula, $VE = 1 - HR$.

The analysis was performed by N. K. S. and A. S. N. using the *survival* package and R version 4.4.2 (R Foundation for Statistical Computing) [11].

RESULTS

A total of 53321 employees in Ohio remained after excluding 1700 subjects (3.1%) for whom age or gender were missing. These employees formed the study cohort and a total of 43771 (82.1%) were vaccinated by the end of the study. The vaccine was the inactivated 3-valent influenza vaccine in 99% of those vaccinated. Altogether, 324 employees (0.61%) acquired influenza during the 17 weeks of the study. Of these, 320 (99%) were influenza A infections, the remaining being influenza B infections. A total of 1904 subjects (3.6%) were censored during the study period because of termination of employment before the end of the study.

Baseline characteristics

Table 1 shows the characteristics of subjects included in the study. Notably, this was a relatively young population, with a mean age of 42 years, and 75% were female.

Influenza vaccine effectiveness

Very few subjects developed influenza A in the first two months of the study and the daily number of infections began to increase steadily about 70 days after the study start date. The cumulative incidence of influenza was not significantly different between the vaccinated and unvaccinated states (Figure 1). The risk of influenza was not significantly different between the vaccinated and unvaccinated states on unadjusted Cox proportional hazards regression (HR, 1.17; 95% C.I. 0.86 - 1.59; $P = 0.31$). However, a higher proportion of the vaccinated than the unvaccinated were tested for influenza on any given day (Supplementary Figure 1). In a multivariable model which adjusted for age, sex, job type (clinical/non-clinical), primary employment location, and eagerness to get vaccinated, the last covariate to adjust for attitude towards influenza with an assumption that testing behavior would be influenced by attitude towards influenza, the risk of influenza was not significantly different between the vaccinated and

unvaccinated states (HR, 1.10; 95% C.I., 0.77 - 1.57; $P = 0.59$). Point estimates and 95% confidence intervals for hazard ratios for acquisition of influenza, for the various variables in multivariable Cox proportional hazards regression models with and without adjustment for eagerness to get vaccinated, are shown in Table 2. Based on the model that adjusted for eagerness to get vaccinated, the influenza vaccine would have had an effectiveness of -10.1% (95% C.I. -57.0 to 22.7%).

DISCUSSION

This study was unable to find a statistically significant difference in time to influenza between the influenza vaccinated and unvaccinated states in northern Ohio during the early part of the 2024-2025 influenza season. This suggests that the influenza vaccine has been either ineffective or of limited effectiveness in preventing the occurrence of influenza during the period examined.

The strengths of our study include a sample size that was large enough to find a clinically significant difference in incidence of influenza between the vaccinated and unvaccinated states, and a study design that allowed for actual calculation of risk rather than an extrapolation from odds ratios obtained from "test-negative" design studies as has become the trend in recent vaccine effectiveness studies. Odds ratios always exaggerate the size of the effect compared with a relative risk and when the event is not rare, as is usually the case in published "test-negative" design studies, this difference can be substantial [12], and that is why estimates of vaccine effectiveness from "test -negative" design studies systematically overestimate true vaccine effectiveness. The study also considered the possibility that testing behavior might differ between the vaccinated and unvaccinated, found that over the course of the study, people in the vaccinated state were about 1.18 times more likely to get tested for influenza than those in the unvaccinated state, and adjusted for this bias by including eagerness to get vaccinated as a marker for attitude towards influenza with the assumption that this attitude would influence influenza testing behavior when ill. The higher risk of influenza with higher eagerness to get vaccinated in the multivariable model suggests that this variable was an effective surrogate for testing behavior as there is no

pathophysiological explanation for higher risk of influenza with getting vaccinated sooner, unless one claims that the vaccine increases the risk of acquiring influenza. The study methodology of treating vaccination as a time-dependent covariate also allowed for determining vaccine effectiveness in real time, which provided us with very early signals about the magnitude of vaccine effectiveness within a few weeks of the first cases of influenza being diagnosed.

The study has several limitations. The confidence interval for the estimate of vaccine effectiveness is wide and does not preclude the possibility of a small beneficial effect. The vaccine was the 3-valent inactivated influenza vaccine in over 99% of our study cohort. The possibility that other influenza vaccines might have been more effective cannot be excluded. Infections diagnosed on the basis of home testing kits alone would have been missed. The study was not designed to compare the risk of influenza-associated hospitalization or mortality, or to examine if the vaccine decreased severity of illness, because these outcomes were not expected to occur in numbers large enough to allow for a meaningful analysis. Our study of healthcare personnel included no children and few elderly subjects, and primarily consisted of individuals who were healthy enough to be employed. A minority would have been expected to have been severely immunocompromised. The study does not exclude the possibility that the vaccine might be more effective later in the season when a different strain of influenza might emerge as the dominant circulating strain.

The results are generalizable to relatively healthy adults in the USA, which is a major target of adult influenza vaccination efforts. Although the study was done in northern Ohio, there is little reason to assume that the effectiveness of the vaccine would have been different in a different geographic region within the continental USA.

Given all the variables that can influence the effectiveness of the influenza vaccine in any given year, it may be asking for too much to expect the vaccine to be highly effective every year, given our current processes for developing the vaccine. It therefore becomes important to evaluate the effectiveness of the vaccine every year. This study was unable to find a protective effect of the influenza vaccine against

influenza among adults in the healthcare workforce in northern Ohio, USA, during the early part of the

2024-2025 winter season.

Notes

Author contributions. N. K. S.: Conceptualization, methodology, validation, investigation, data curation, software, formal analysis, visualization, writing- original draft preparation, writing- reviewing and editing, supervision, project administration. P. C. B.: Resources, investigation, validation, writing- reviewing and editing. A. S. N.: Methodology, formal analysis, visualization, validation, writing- reviewing and editing. S. M. G.: Resources, writing- reviewing and editing.

Potential conflicts of interest. The authors: No reported conflicts of interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Funding. None.

REFERENCES

1.   GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med **2019**; 7:69–89.

2.   Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis **2006**; 12:15–22.

3.   Lofgren E, Fefferman NH, Naumov YN, Gorski J, Naumova EN. Influenza Seasonality: Underlying Causes and Modeling Theories. J Virol **2007**; 81:5429–5436.

4.   Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol **2018**; 16:47–60.

5.   Wong S-S, Webby RJ. Traditional and New Influenza Vaccines. Clin Microbiol Rev **2013**; 26:476–492.

6.   Grohskopf LA. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–25 Influenza Season. MMWR Recomm Rep **2024**; 73. Available at: https://www.cdc.gov/mmwr/volumes/73/rr/rr7305a1.htm. Accessed 28 November 2024.

7.   Greene MT, Linder KA, Fowler KE, Saint S. Influenza Vaccination Requirements for Health Care Personnel in US Hospitals. JAMA Netw Open **2024**; 7:e2416861.

8.   Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non-responder bias. Stat Med **1984**; 3:35–44.

9.   Therneau TM, Crowson C, Atkinson E. Using time dependent covariates and time dependent coefficients in the Cox model. **2021**; Available at: https://cran.r-project.org/web/packages/survival/vignettes/timedep.pdf. Accessed 8 May 2021.

10.   Therneau TM, Grambsh, PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer International Publishing, **2000**.

11.   R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, **2024**.

12.   Davies HTO, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ **1998**; 316:989–991.

TABLES

Table 1

Table 1. Baseline characteristics of 53321 employees of Cleveland Clinic in Ohio

Characteristics	Overall[a]
Age in years, mean (SD)	42.1 (13.4)
Sex	
Female	40 068 (75.1)
Male	13 253 (24.9)
Primary work location	
Cleveland Clinic Main	20 516 (38.5)
Regional hospitals[b]	21 830 (40.9)
Ambulatory centers	9342 (17.5)
Administrative centers	1633 (3.1)
Human resources job classification	
Clinical	39 974(75.0)
Non-clinical	13 347 (25.0)
Eagerness to get vaccinated	
High	29 232 (54.8)
Low	24 089 (45.2)

[a]Data are presented as no. (%) unless otherwise indicated.

[b]Includes Akron General, Ashtabula, Euclid, Fairview, Hillcrest, Lodi Community, Lutheran, Marymount, Medina, Mentor, Mercy (Canton), Southpointe, and Union, hospitals, all part of the Cleveland Clinic Health System.

Table 2

Table 2. Adjusted Associations with Time to Influenza in Cox Proportional Hazards Regression Models

Characteristics	Without adjustment for eagerness to get vaccinated		Including adjustment for eagerness to get vaccinated	
	HR (95% CI)[a]	*P*	HR (95% CI)[a]	*P*
Vaccinated state[b]	1.19 (.88-1.62)	.26	1.10 (.77-1.57)	.59
Age	.987 (.979-.996)	.004	.987 (.979-.996)	.004
Male sex[c]	.69 (.52-.92)	.01	.69 (.52-.92)	.01
Non-clinical job[d]	.93 (.71-1.21)	.58	.93 (.71-1.21)	.59
Primary work location[e]				
Administrative centers	.95 (.48-1.87)	.88	.95 (.48-1.88)	.89
Ambulatory centers	1.35 (1.02-1.80)	.04	1.35 (1.02-1.80)	.04
Regional hospitals	.79 (.61-1.03)	.08	.79 (.61-1.02)	.08)
High eagerness to get vaccinated[f]	-	-	1.12 (.87-1.45)	.37

Abbreviation: CI, confidence interval; HR, hazard ratio; COVID-19, Coronavirus Disease 2019;

[a]From multivariable Cox-proportional hazards regression models with bivalent vaccinated state treated as a time-dependent covariate.

[b]Time-dependent covariate

[c]Reference is female sex

[d]Reference is clinical job

[e]Reference is Cleveland Clinic Main Campus

[f]Reference is low

FIGURE LEGENDS

Figure 1. Simon-Makuch plot comparing the cumulative incidence of influenza for subjects stratified by vaccination status. Day zero was 1 October 2024, the day the influenza vaccine began to be offered to employees for the respiratory viral season. Point estimates and 95% confidence intervals are jittered along the x-axis to improve visibility.

Supplementary Figure 1. Comparison of the ratio of the proportion of vaccinated tested to the proportion of unvaccinated tested for influenza on each day of the study. The dashed line represents the reference line where the testing proportions are the same for those vaccinated and unvaccinated. Days on which a higher proportion of vaccinated than non-vaccinated individuals were tested for influenza are represented by dots above the reference line, and days on which a lower proportion of vaccinated than non-vaccinated individuals were tested for influenza are represented by dots below the reference line. The red line represents the best fit line by linear regression, after excluding outliers (values >3 standard deviations from the mean ratio). The line had an intercept of 1.18 and a slope of 0.0030; and the slope was not significantly different from zero (*P* value 0.174).

Numbers at risk:

-----Not vaccinated	53321	40780	23831	9643	9301	9106	8948	8783	8656
____ Vaccinated	0	12449	29145	43026	43160	43105	43009	42807	42615